GHENT, Belgium, June 16, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] issued a correction regarding a transparency notification received on 13 June 2016, pursuant to the Belgian transparency legislation (Belgian Act of 2 May 2007) concerning major holdings in Belgian listed companies.
Adrianus van Herk (not van Herk Investments as erroneously stated in the press release of 16 June 2016 at 07:00 am CET) notified Ablynx that he has exceeded the 3% threshold on 13 June 2016 and now holds 1,835,276 Ablynx shares, representing 3.02% of the current 60,870,926 outstanding Ablynx shares.
Full versions of all transparency notifications are available on Ablynx website, under the section Investors.
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Follow us on Twitter @AblynxABLX
Ablynx media/analyst relations
Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss
t: +44 20 3727 1000
pdf format of the press release http://hugin.info/137912/R/2021181/750845.pdf